Nanobiotix completes dose escalation-expansion parts of NBTXR3 in PC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2024
0mins
Phase 1 Study Completion: Nanobiotix has completed the dose escalation and expansion phases of a Phase 1 study on NBTXR3 for treating locally advanced or borderline resectable pancreatic cancer, conducted at MD Anderson Cancer Center.
New Study Cohort Initiated: Following positive results, MD Anderson received FDA clearance to start a new cohort combining NBTXR3 with standard concurrent chemoradiation, with ongoing recruitment and full results expected in early 2025.
Analyst Views on NBTX
Wall Street analysts forecast NBTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is 24.00 USD with a low forecast of 24.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 21.170
Low
24.00
Averages
24.00
High
24.00
Current: 21.170
Low
24.00
Averages
24.00
High
24.00
About NBTX
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
